Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium.

Lagergren K, Ek WE, Levine D, Chow WH, Bernstein L, Casson AG, Risch HA, Shaheen NJ, Bird NC, Reid BJ, Corley DA, Hardie LJ, Wu AH, Fitzgerald RC, Pharoah P, Caldas C, Romero Y, Vaughan TL, MacGregor S, Whiteman D, Westberg L, Nyren O, Lagergren J.

PLoS One. 2015 Sep 25;10(9):e0138738. doi: 10.1371/journal.pone.0138738. eCollection 2015.

2.

Waiting for scheduled surgery: A complex patient experience.

Carr T, Teucher U, Casson AG.

J Health Psychol. 2017 Mar;22(3):290-301. doi: 10.1177/1359105315603464. Epub 2016 Jul 10.

PMID:
26349617
3.

MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium.

Buas MF, Onstad L, Levine DM, Risch HA, Chow WH, Liu G, Fitzgerald RC, Bernstein L, Ye W, Bird NC, Romero Y, Casson AG, Corley DA, Shaheen NJ, Wu AH, Gammon MD, Reid BJ, Hardie LJ, Peters U, Whiteman DC, Vaughan TL.

PLoS One. 2015 Jun 3;10(6):e0128617. doi: 10.1371/journal.pone.0128617. eCollection 2015.

4.

Cigarette smoke mediates epigenetic repression of miR-217 during esophageal adenocarcinogenesis.

Xi S, Inchauste S, Guo H, Shan J, Xiao Z, Xu H, Miettenen M, Zhang MR, Hong JA, Raiji MT, Altorki NK, Casson AG, Beer DG, Robles AI, Bowman ED, Harris CC, Steinberg SM, Schrump DS.

Oncogene. 2015 Oct 29;34(44):5548-59. doi: 10.1038/onc.2015.10. Epub 2015 Feb 23.

5.

Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus.

Palles C, Chegwidden L, Li X, Findlay JM, Farnham G, Castro Giner F, Peppelenbosch MP, Kovac M, Adams CL, Prenen H, Briggs S, Harrison R, Sanders S, MacDonald D, Haigh C, Tucker A, Love S, Nanji M, deCaestecker J, Ferry D, Rathbone B, Hapeshi J, Barr H, Moayyedi P, Watson P, Zietek B, Maroo N, Gay L, Underwood T, Boulter L, McMurtry H, Monk D, Patel P, Ragunath K, Al Dulaimi D, Murray I, Koss K, Veitch A, Trudgill N, Nwokolo C, Rembacken B, Atherfold P, Green E, Ang Y, Kuipers EJ, Chow W, Paterson S, Kadri S, Beales I, Grimley C, Mullins P, Beckett C, Farrant M, Dixon A, Kelly S, Johnson M, Wajed S, Dhar A, Sawyer E, Roylance R, Onstad L, Gammon MD, Corley DA, Shaheen NJ, Bird NC, Hardie LJ, Reid BJ, Ye W, Liu G, Romero Y, Bernstein L, Wu AH, Casson AG, Fitzgerald R, Whiteman DC, Risch HA, Levine DM, Vaughan TL, Verhaar AP, van den Brande J, Toxopeus EL, Spaander MC, Wijnhoven BP, van der Laan LJ, Krishnadath K, Wijmenga C, Trynka G, McManus R, Reynolds JV, O'Sullivan J, MacMathuna P, McGarrigle SA, Kelleher D, Vermeire S, Cleynen I, Bisschops R, Tomlinson I, Jankowski J.

Gastroenterology. 2015 Feb;148(2):367-78. doi: 10.1053/j.gastro.2014.10.041. Epub 2014 Nov 5.

6.

Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.

Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, Shaheen NJ, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, Liu G, Corley DA, Blount PL, Fitzgerald RC, Whiteman DC, Wu AH, Reid BJ, Vaughan TL.

Carcinogenesis. 2014 Dec;35(12):2740-7. doi: 10.1093/carcin/bgu207. Epub 2014 Oct 3.

7.

Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study.

Thrift AP, Shaheen NJ, Gammon MD, Bernstein L, Reid BJ, Onstad L, Risch HA, Liu G, Bird NC, Wu AH, Corley DA, Romero Y, Chanock SJ, Chow WH, Casson AG, Levine DM, Zhang R, Ek WE, MacGregor S, Ye W, Hardie LJ, Vaughan TL, Whiteman DC.

J Natl Cancer Inst. 2014 Sep 30;106(11). pii: dju252. doi: 10.1093/jnci/dju252. Print 2014 Nov.

8.

Time while waiting: patients' experiences of scheduled surgery.

Carr T, Teucher UC, Casson AG.

Qual Health Res. 2014 Dec;24(12):1673-85. doi: 10.1177/1049732314549022. Epub 2014 Sep 5.

PMID:
25192766
9.

Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON).

Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, Gammon MD, Risch HA, Casson AG, Freedman ND, Chow WH, Wu AH, Bernstein L, Nyrén O, Pandeya N, Whiteman DC, Vaughan TL.

PLoS One. 2014 Jul 30;9(7):e103508. doi: 10.1371/journal.pone.0103508. eCollection 2014.

10.

Telomerase variant A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas.

Zhang Y, Calado R, Rao M, Hong JA, Meeker AK, Dumitriu B, Atay S, McCormick PJ, Garfield SH, Wangsa D, Padilla-Nash HM, Burkett S, Zhang M, Kunst TF, Peterson NR, Xi S, Inchauste S, Altorki NK, Casson AG, Beer DG, Harris CC, Ried T, Young NS, Schrump DS.

PLoS One. 2014 Jul 1;9(7):e101010. doi: 10.1371/journal.pone.0101010. eCollection 2014.

11.

Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization.

Thrift AP, Risch HA, Onstad L, Shaheen NJ, Casson AG, Bernstein L, Corley DA, Levine DM, Chow WH, Reid BJ, Romero Y, Hardie LJ, Liu G, Wu AH, Bird NC, Gammon MD, Ye W, Whiteman DC, Vaughan TL.

Clin Gastroenterol Hepatol. 2014 Oct;12(10):1667-76.e1. doi: 10.1016/j.cgh.2014.01.039. Epub 2014 Feb 12.

12.

Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux.

Ek WE, Levine DM, D'Amato M, Pedersen NL, Magnusson PK, Bresso F, Onstad LE, Schmidt PT, Törnblom H, Nordenstedt H, Romero Y; Mayo Clinic Esophageal Adenocarcinoma and Barrett’s Esophagus Registry Consortium, Chow WH, Murray LJ, Gammon MD, Liu G, Bernstein L, Casson AG, Risch HA, Shaheen NJ, Bird NC, Reid BJ, Corley DA, Hardie LJ, Ye W, Wu AH, Zucchelli M, Spector TD, Hysi P, Vaughan TL, Whiteman DC, MacGregor S; BEACON study investigators.

J Natl Cancer Inst. 2013 Nov 20;105(22):1711-8. doi: 10.1093/jnci/djt303. Epub 2013 Oct 29.

13.

A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus.

Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, Lao-Sirieix P, Gammon MD, Corley DA, Shaheen NJ, Bird NC, Hardie LJ, Murray LJ, Reid BJ, Chow WH, Risch HA, Nyrén O, Ye W, Liu G, Romero Y, Bernstein L, Wu AH, Casson AG, Chanock SJ, Harrington P, Caldas I, Debiram-Beecham I, Caldas C, Hayward NK, Pharoah PD, Fitzgerald RC, Macgregor S, Whiteman DC, Vaughan TL.

Nat Genet. 2013 Dec;45(12):1487-93. doi: 10.1038/ng.2796. Epub 2013 Oct 13.

14.

Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium.

Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, Brown LM, Risch HA, Ye W, Sharp L, Wu AH, Ward MH, Casson AG, Murray LJ, Corley DA, Nyrén O, Pandeya N, Vaughan TL, Chow WH, Gammon MD.

Int J Epidemiol. 2012 Dec;41(6):1706-18. doi: 10.1093/ije/dys176. Epub 2012 Nov 12.

15.

Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines.

Zhao R, Quaroni L, Casson AG.

J Thorac Cardiovasc Surg. 2012 Nov;144(5):1192-9. doi: 10.1016/j.jtcvs.2012.08.008. Epub 2012 Sep 12.

16.

Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus.

Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, Lescai F, Langford C, Nanji M, Edkins S, van der Winkel A, Levine D, Sasieni P, Bellenguez C, Howarth K, Freeman C, Trudgill N, Tucker AT, Pirinen M, Peppelenbosch MP, van der Laan LJ, Kuipers EJ, Drenth JP, Peters WH, Reynolds JV, Kelleher DP, McManus R, Grabsch H, Prenen H, Bisschops R, Krishnadath K, Siersema PD, van Baal JW, Middleton M, Petty R, Gillies R, Burch N, Bhandari P, Paterson S, Edwards C, Penman I, Vaidya K, Ang Y, Murray I, Patel P, Ye W, Mullins P, Wu AH, Bird NC, Dallal H, Shaheen NJ, Murray LJ, Koss K, Bernstein L, Romero Y, Hardie LJ, Zhang R, Winter H, Corley DA, Panter S, Risch HA, Reid BJ, Sargeant I, Gammon MD, Smart H, Dhar A, McMurtry H, Ali H, Liu G, Casson AG, Chow WH, Rutter M, Tawil A, Morris D, Nwokolo C, Isaacs P, Rodgers C, Ragunath K, MacDonald C, Haigh C, Monk D, Davies G, Wajed S, Johnston D, Gibbons M, Cullen S, Church N, Langley R, Griffin M, Alderson D, Deloukas P, Hunt SE, Gray E, Dronov S, Potter SC, Tashakkori-Ghanbaria A, Anderson M, Brooks C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Duncanson A, Markus HS, Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood N, Trynka G, Wijmenga C, Cazier JB, Atherfold P, Nicholson AM, Gellatly NL, Glancy D, Cooper SC, Cunningham D, Lind T, Hapeshi J, Ferry D, Rathbone B, Brown J, Love S, Attwood S, MacGregor S, Watson P, Sanders S, Ek W, Harrison RF, Moayyedi P, de Caestecker J, Barr H, Stupka E, Vaughan TL, Peltonen L, Spencer CC, Tomlinson I, Donnelly P, Jankowski JA; Esophageal Adenocarcinoma Genetics Consortium; Wellcome Trust Case Control Consortium 2.

Nat Genet. 2012 Oct;44(10):1131-6. doi: 10.1038/ng.2408. Epub 2012 Sep 9.

17.

The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium.

Lubin JH, Cook MB, Pandeya N, Vaughan TL, Abnet CC, Giffen C, Webb PM, Murray LJ, Casson AG, Risch HA, Ye W, Kamangar F, Bernstein L, Sharp L, Nyrén O, Gammon MD, Corley DA, Wu AH, Brown LM, Chow WH, Ward MH, Freedman ND, Whiteman DC.

Cancer Epidemiol. 2012 Jun;36(3):306-16. doi: 10.1016/j.canep.2012.03.001. Epub 2012 Apr 13.

18.

Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis.

Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, Abnet CC, Risch HA, Giffen C, Freedman ND, Chow WH, Sadeghi S, Pandeya N, Whiteman DC, Murray LJ, Bernstein L, Gammon MD, Wu AH.

Gastroenterology. 2012 Mar;142(3):442-452.e5; quiz e22-3. doi: 10.1053/j.gastro.2011.11.019. Epub 2011 Nov 19.

19.

Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium.

Freedman ND, Murray LJ, Kamangar F, Abnet CC, Cook MB, Nyrén O, Ye W, Wu AH, Bernstein L, Brown LM, Ward MH, Pandeya N, Green AC, Casson AG, Giffen C, Risch HA, Gammon MD, Chow WH, Vaughan TL, Corley DA, Whiteman DC.

Gut. 2011 Aug;60(8):1029-37. doi: 10.1136/gut.2010.233866. Epub 2011 Mar 14.

20.

Loss of imprinting and abnormal expression of the insulin-like growth factor 2 gene in gastric cancer.

Zuo QS, Yan R, Feng DX, Zhao R, Chen C, Jiang YM, Cruz-Correa M, Casson AG, Kang XD, Han F, Chen T.

Mol Carcinog. 2011 May;50(5):390-6. doi: 10.1002/mc.20731. Epub 2011 Jan 25.

PMID:
21268128
21.

Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma.

Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkes JE, Mathé EA, Kumamoto K, Zhao Y, Budhu A, Hagiwara N, Wang XW, Miyashita M, Casson AG, Harris CC.

Clin Cancer Res. 2010 Dec 1;16(23):5824-34. doi: 10.1158/1078-0432.CCR-10-1110. Epub 2010 Oct 14.

22.

Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium.

Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, Brown LM, Risch HA, Ye W, Sharp L, Pandeya N, Webb PM, Wu AH, Ward MH, Giffen C, Casson AG, Abnet CC, Murray LJ, Corley DA, Nyrén O, Vaughan TL, Chow WH.

J Natl Cancer Inst. 2010 Sep 8;102(17):1344-53. doi: 10.1093/jnci/djq289. Epub 2010 Aug 17.

23.

Obesity is not associated with adverse outcome following surgical resection of oesophageal adenocarcinoma.

Madani K, Zhao R, Lim HJ, Casson SM, Casson AG.

Eur J Cardiothorac Surg. 2010 Nov;38(5):604-8. doi: 10.1016/j.ejcts.2010.03.054. Epub 2010 May 4. Erratum in: Eur J Cardiothorac Surg. 2010 Dec;38(6):820-1.

PMID:
20444616
24.

Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study.

Madani K, Zhao R, Lim HJ, Casson AG.

Eur J Cardiothorac Surg. 2010 Jun;37(6):1427-32. doi: 10.1016/j.ejcts.2009.12.018. Epub 2010 Mar 12.

PMID:
20227286
25.

Regulation of fibroblast growth factor-2 by an endogenous antisense RNA and by argonaute-2.

MacFarlane LA, Gu Y, Casson AG, Murphy PR.

Mol Endocrinol. 2010 Apr;24(4):800-12. doi: 10.1210/me.2009-0367. Epub 2010 Mar 2.

26.

Dietary folate and vitamin B6 are not associated with p53 mutations in esophageal adenocarcinoma.

Balbuena L, Casson AG.

Mol Carcinog. 2010 Mar;49(3):211-4. doi: 10.1002/mc.20602.

PMID:
20025073
27.

Fourier transform infrared (FTIR) spectromicroscopic characterization of stem-like cell populations in human esophageal normal and adenocarcinoma cell lines.

Zhao R, Quaroni L, Casson AG.

Analyst. 2010 Jan;135(1):53-61. doi: 10.1039/b914311d. Epub 2009 Nov 10.

PMID:
20024181
28.

Photofrin PDT for early stage esophageal cancer: a new standard of care?

Casson AG.

Photodiagnosis Photodyn Ther. 2009 Sep-Dec;6(3-4):155-6. doi: 10.1016/j.pdpdt.2009.09.002. Epub 2009 Oct 2. No abstract available.

PMID:
19932445
29.

Shining light on Barrett's esophagus.

Quaroni L, Zhao R, Casson AG.

Expert Rev Gastroenterol Hepatol. 2009 Dec;3(6):577-80. doi: 10.1586/egh.09.43. No abstract available.

PMID:
19929578
30.

Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues.

Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui H, Casson AG.

Carcinogenesis. 2009 Dec;30(12):2117-22. doi: 10.1093/carcin/bgp254.

PMID:
19843644
31.

Physical activity, obesity and risk for esophageal adenocarcinoma.

Balbuena L, Casson AG.

Future Oncol. 2009 Sep;5(7):1051-63. doi: 10.2217/fon.09.65. Review.

PMID:
19792973
32.

MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.

Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC.

Clin Cancer Res. 2009 Oct 1;15(19):6192-200. doi: 10.1158/1078-0432.CCR-09-1467. Epub 2009 Sep 29.

33.

A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma.

MacDonald K, Porter GA, Guernsey DL, Zhao R, Casson AG.

Cancer Epidemiol. 2009 Jul;33(1):37-40. doi: 10.1016/j.canep.2009.04.014. Epub 2009 May 28.

PMID:
19679045
34.

Insulin-like growth factor type I receptor gene expression and obesity in esophageal adenocarcinoma.

Zhao R, Macdonald K, Casson AG.

Mol Carcinog. 2009 Nov;48(11):982-8. doi: 10.1002/mc.20562.

PMID:
19582762
35.

Characterization of Barrett esophagus and esophageal adenocarcinoma by Fourier-transform infrared microscopy.

Quaroni L, Casson AG.

Analyst. 2009 Jun;134(6):1240-6. doi: 10.1039/b823071d. Epub 2009 Feb 11.

PMID:
19475154
36.

Regulation of CDX2 expression in esophageal adenocarcinoma.

Vaninetti N, Williams L, Geldenhuys L, Porter GA, Guernsey DL, Casson AG.

Mol Carcinog. 2009 Oct;48(10):965-74. doi: 10.1002/mc.20549.

PMID:
19415720
37.

Waiting for surgery from the patient perspective.

Carr T, Teucher U, Mann J, Casson AG.

Psychol Res Behav Manag. 2009;2:107-19. Epub 2009 Oct 14.

38.

Epigenetic aberrations and targeted epigenetic therapy of esophageal cancer.

Zhao R, Casson AG.

Curr Cancer Drug Targets. 2008 Sep;8(6):509-21. Review.

PMID:
18781897
39.

Does previous fundoplication alter the surgical approach to esophageal adenocarcinoma?

Casson AG, Madani K, Mann S, Zhao R, Reeder B, Lim HJ.

Eur J Cardiothorac Surg. 2008 Nov;34(5):1097-101; discussion 1101-2. doi: 10.1016/j.ejcts.2008.07.059. Epub 2008 Sep 6.

PMID:
18774726
40.

Alternative splicing and differential subcellular localization of the rat FGF antisense gene product.

Zhang SC, MacDonald KA, Baguma-Nibasheka M, Geldenhuys L, Casson AG, Murphy PR.

BMC Mol Biol. 2008 Jan 23;9:10. doi: 10.1186/1471-2199-9-10.

41.

Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.

Vaninetti NM, Geldenhuys L, Porter GA, Risch H, Hainaut P, Guernsey DL, Casson AG.

Mol Carcinog. 2008 Apr;47(4):275-85.

PMID:
17849424
42.

Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma.

Williams LJ, Guernsey DL, Casson AG.

Curr Oncol. 2006 Feb;13(1):33-43.

43.

Alternative splicing of the FGF antisense gene: differential subcellular localization in human tissues and esophageal adenocarcinoma.

Zhang SC, Barclay C, Alexander LA, Geldenhuys L, Porter GA, Casson AG, Murphy PR.

J Mol Med (Berl). 2007 Nov;85(11):1215-28. Epub 2007 Jun 14.

PMID:
17569023
44.

Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma.

Baguma-Nibasheka M, Barclay C, Li AW, Geldenhuys L, Porter GA, Blay J, Casson AG, Murphy PR.

Mol Carcinog. 2007 Dec;46(12):971-80.

PMID:
17477358
45.
46.

Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma.

Veugelers PJ, Porter GA, Guernsey DL, Casson AG.

Dis Esophagus. 2006;19(5):321-8.

PMID:
16984526
47.

Validation of the functional assessment of cancer therapy esophageal cancer subscale.

Darling G, Eton DT, Sulman J, Casson AG, Celia D.

Cancer. 2006 Aug 15;107(4):854-63.

48.

Suppurative mediastinitis secondary to Burkholderia cepacia in a patient with cystic fibrosis.

George RB, Cartier Y, Casson AG, Hernandez P.

Can Respir J. 2006 May-Jun;13(4):215-8.

49.

Salvage PDT for persistent esophageal cancer after chemoradiotherapy.

Casson AG.

Photodiagnosis Photodyn Ther. 2006 Mar;3(1):15-6. doi: 10.1016/S1572-1000(06)00004-4. Epub 2006 Feb 20. No abstract available.

PMID:
25049022
50.

Epidemiology and molecular biology of Barrett esophagus.

Casson AG, Williams L, Guernsey DL.

Semin Thorac Cardiovasc Surg. 2005 Winter;17(4):284-91. Review.

PMID:
16428034

Supplemental Content

Loading ...
Support Center